Epizyme, Inc. (NASDAQ:EPZM) is reporting third quarter financial results on Friday 6th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, EPZM is expected to report 3Q20 loss of $ 0.6 per share from revenue of $ 5.43 million.
For the full year, analysts anticipate top line of $ 19.60 million, while looking forward to loss of $ 2.39 per share bottom line.
Previous Quarter Performance
Epizyme, Inc. unwinded loss for the second quarter of $ 0.58 per share, from the revenue of $ 2.47 million. The quarterly revenues reduced 58.14 percent compared with the same quarter last year. According to street consensus, EPZM was expected to report 2Q20 loss of $ 0.61 per share from revenue of $ 4.30 million. The bottom line results beat street analysts by $ 0.03 or 4.92 percent, at the same time, top line results fell short of analysts by $ 1.83 million or 42.56 percent.
Stock Performance
Shares of Epizyme, Inc. traded up $ 0.45 or 3.44 percent on Thursday, reaching $ 13.55 with volume of 687.80 thousand shares. Epizyme, Inc. has traded high as $ 13.69 and has cracked $ 12.76 on the downward trend
According to the previous trading day, closing price of $ 13.55, representing a 18.77 % increase from the 52 week low of $ 11.03 and a 52.91 % decrease over the 52 week high of $ 27.82.
The company has a market capital of $ 1.38 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Epizyme, Inc. will be hosting a conference call at 8:00 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.epizyme.com
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The companys lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer.
